• Ironwood Pharmaceuticals raised fiscal 2026 LINZESS U.S. net sales guidance to $1.2 billion–$1.25 billion from $1.15 billion–$1.2 billion.
• Total revenue guidance increased to $485 million–$510 million from $460 million–$485 million.
• Adjusted EBITDA is now forecast above $350 million, up from above $310 million.
• The second consecutive quarterly guidance increase followed third-quarter LINZESS U.S. net sales of $325 million, up 3% year over year.
• Year-to-date sales rose 25% to $880 million, driven by improved net pricing and 5% prescription demand growth.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ironwood Pharmaceuticals Inc. published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.